ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Piribedil attenuates methotrexate-induced nephrotoxicity in rats: associated changes in miR-205/EGLN2, Nrf2, and PERK/ATF4/CHOP-related stress responses.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Although microRNAs have been investigated, the renoprotective role of microRNA-205 (miR-205) in methotrexate (MTX)-induced nephrotoxicity remains unclear. Accordingly, this study examined changes in miR-205 and its established target EGLN2 in relation to oxidative and endoplasmic reticulum stress responses during piribedil treatment. Rats were randomly divided into four groups (n = 8/group): a normal control group, an MTX group that received a single intraperitoneal injection of methotrexate (20 mg/kg) on day 7, and two piribedil-treated groups that received piribedil orally at 25 or 50 mg/kg/day for 10 consecutive days, with MTX administered on day 7. At the end of the study, blood and kidney samples were collected for biochemical, histopathological, immunohistochemical, and qRT-PCR analyses. MTX induced significant renal impairment, as indicated by increased SCr, BUN, NGAL, and KIM-1, together with marked histopathological alterations. These changes were accompanied by decreased miR-205 and increased EGLN2 expression, alterations in Nrf2-related antioxidant markers, elevated PC levels, and increased PERK/eIF2α/ATF4/CHOP-related ER-stress markers (p < 0.01). In parallel, MTX increased JNK1 and FOS expression, NF-κB p65 immunoreactivity, pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), and apoptosis-related markers including caspase-12, caspase-9, and caspase-3 (p < 0.01). Piribedil attenuated renal functional and structural injury, accompanied by reciprocal changes in miR-205/EGLN2 expression and improvement in the investigated antioxidant, ER-stress-, inflammatory-, and apoptosis-related markers. These findings support further evaluation of piribedil as a potential renoprotective agent and indicate that its protective effect in MTX-induced renal injury is accompanied by alterations in miR-205/EGLN2 expression and related cellular stress-response markers.
Indexed as
Identifiers
42839047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.